Reconciling Neurophysiology, Research Ethics, and the Evolving Care of Intersex Individuals

Human biology is remarkably adept at challenging our oldest scientific assumptions. For those deeply entrenched in clinical neurophysiology and medical education, populations with Differences of Sex Development [DSD] encompassing a spectrum of congenital conditions where chromosomal, gonadal, or anatomical sex characteristics diverge from binary expectations oblige us to completely rethink the traditional tenets of sexual differentiation. These variations compel us to untangle the distinct influences of genetics, endocrine exposure, and psychosocial environment on the developing brain. As our diagnostic tools grow more sophisticated, the scientific and medical communities must urgently replace outdated, essentialist models with nuanced, affirming, and evidence-based frameworks [1,2,3].

Historically, the neurohormonal theory of brain sexual differentiation dictated that prenatal androgen exposure exclusively drove the masculinization or feminization of neural structures. Recent large-scale neuroimaging studies have fundamentally disrupted this narrative. Analyses of gray matter, white matter microstructure, and connectomics reveal extensive, complex overlap between the sexes. Rather than falling into two discrete categories, the human brain is now understood as a highly individualized “mosaic” of features [1].

For individuals with DSDs, this mosaicism establishes a crucial neurobiological baseline. It proves that atypical chromosomal or hormonal profiles do not result in a “disordered” brain, but rather reflect the natural variance inherent in human neurodevelopment.

The most significant shift in the neuropsychological care of intersex individuals is currently being driven by updated psychiatric diagnostic manuals, which actively work to de-pathologize intersex traits. The World Health Organization’s ICD-11 officially removed gender incongruence from the classification of mental disorders [2]. Similarly, the DSM-5-TR explicitly allows the diagnosis of Gender Dysphoria to be applied to individuals with DSDs, conceptually separating psychiatric distress from the biological variation itself [4].

This distinction is vital for modern pedagogical frameworks. As educators and clinicians, we must recognize that the psychological burden carried by intersex individuals rarely stems from their biology, but rather from the intense social pressure to conform to a binary system. Qualitative research highlights that intersex individuals frequently experience profound shame, low self-esteem, and severe social isolation as a direct result of trying to fit into rigid, culturally imposed dichotomies. Furthermore, a pervasive culture of family and medical secrecy often leads to delayed diagnoses and fractured interpersonal relationships, heavily impacting their overall quality of life [5].

Our push to align care with human rights frameworks must also rigorously scrutinize the language and visual tools we utilize in clinical literature and research ethics. A recent scoping review highlights a pervasive issue within medical publications regarding DSD: the uncritical, “sleeping” metaphor of “normality”. Researchers frequently rely on purely subjective evaluations of “normal appearance” to justify early, irreversible surgical interventions on pediatric populations.This unexamined language inherently pathologizes natural biological variance. Even our terminology remains contested; while the medical establishment heavily utilizes the acronym “DSD,” many individuals associate this term with negative, pathological connotations, strongly preferring the term “intersex” as an affirming identifier [6].

Perhaps most troubling is how the medical gaze has historically been weaponized against this population. A review of recent literature reveals a glaring ethical blind spot: over a third of analyzed clinical case studies publish intimate medical photographs of intersex infants and children without explicitly reporting informed consent for their publication. Compounding this, adult intersex patients frequently report degrading treatment, a lack of empathy during diagnosis, and severe violations of privacy during medical examinations—such as being displayed to cohorts of students without prior consent. For those shaping medical curricula and managing ethics committees, these findings present a clear mandate to reform how clinical observation and patient privacy are balanced in teaching environments [7].

Prioritizing anatomical conformity over psychological well-being is an outdated and potentially harmful metric. Aligning with an agency-based model of intersex health, modern regulations demand the cessation of “normalizing” procedures that serve cultural binarism rather than urgent physiological necessity [3]. Irreversible interventions must be deferred until the individual has the neurocognitive maturity to participate fully in shared decision-making [8].

Achieving this requires comprehensive, well-funded multidisciplinary teams that heavily integrate mental health professionals. Care teams must prioritize psychosocial support, dismantle deeply held prejudices through rigorous educational campaigns for healthcare providers, and champion legislation that fiercely protects the human rights of the intersex community.

The neurobiopsychology of intersex variations illuminates a fundamental truth: sex and gender are multidimensional, emergent properties of a complex biological and social system. Our mandate is to align our neuroscientific inquiries with ethical guidelines that champion healthcare equity. By integrating advanced neurophysiology with compassionate, trauma-informed, and depathologizing care, we can foster a scientific environment that not only respects the diversity of the human brain but actively protects the individuals who possess it.

None.

No Conflict of interest.

1. Abascal JV, Alvarez PB, Rosales FM, Ramirez AF, Khalil MIA, et al. (2014) First case with Huntington's disease in The Gambia. Journal of the Neurological Sciences 338: 238-240.
2. Aiyesimoju AB, Osuntokun BO, Bademosi O, Adeuja AO (1984) Hereditary neurodegenerative disorders in Nigerian Africans. Neurology 34: 361-362.
3. Andrew SE, Goldberg YP, Kremer B, et al. (1994) Huntington disease without CAG expansion: phenocopies or errors in assignment? Am J Hum Genet 54: 852-863.
4. Assami S, Azzedine H, Nouioua S, Mundwiller E, Mahoui S, et al. (2011) Pantothenate Kinase–Associated Neurodegeneration: Clinical Description of 10 Patients and Identification of New Mutations. Movement Disorders 26 (9): 1777-1779.
5. Baine FK, Kay C, Ketelaar ME, et al. (2013) Huntington disease in the South African population occurs on diverse and ethnically distinct genetic haplotypes. Eur J Hum Genet 21(10): 1120-1127.
6. Baine F, Krause A, Greenberg L (2016) The frequency of Huntington disease and Huntington disease-like 2 in the South African population. Neuroepidemiology 46(3): 198-202.
7. Baine FK, Peerbhai N, Krause A (2018) A study of Huntington disease-like syndromes in black South African patients reveals a single SCA2 mutation and a unique distribution of normal alleles across five repeat loci. Journal of the Neurological Sciences 390: 200-204.
8. Bardien S, Abrahams F, Soodyall H, Merwe LVD, Greenberg J, et al. (2007) A South African Mixed Ancestry Family with Huntington Disease-Like 2: Clinical and Genetic Features. Movement Disorders 22(14): 2083-2089.
9. BATES G, HARPER PS, JONES L (editors) (2002) Huntington’s disease, 3rd ed. Oxford: Oxford University Press.
10. Bouhouche A, Regragui W, Lamghari H, Khaldi K, Birouk N, et al. (2015) Clinical and genetic data of Huntington disease in Moroccan patients. Afri Health Sci 15(4): 1232-1238.
11. Coulibaly T, Karambe M, Guinto CO, Traore M (2012) Huntington's disease confirmed by genetic testing in three Malian families. Mov Disord; 27(Suppl.1): 171.
12. Donaldson I, Marsden CD, Schneider SA, Bhatia KB (2012) Clinical approach to movement disorders. In Marsden's Book of Movement Disorders. Donaldson I, Marsden CD, Schneider SA, Bhatia KB. Editors. Oxford, United Kingdom: Oxford University Press 140-141.
13. Gregory A, Polster BJ, Hayflick SJ (2008) Clinical and genetic delineation of neurodegeneration with brain iron accumulation. J Med Genet 46(2): 73-80.
14. Kaboré J, Ouédraogo A (2000) Huntington disease in Burkina Faso. Rev Neurol (Paris) 156(12): 1157-1158.
15. Krause A, Mitchell C, Essop F, Tager S, Temlett J, et al. (2015) Junctophilin 3 (JPH3) expansion mutations caus- ing Huntington disease like 2 (HDL2) are common in South African patients with African ancestry and a Huntington disease phenotype. Am J Med Genet B Neuropsychiatr Genet 168(7): 573-585.
16. Krause A, Temlett J, Van Der Meyden K, Ross CA, Callahan C, Margolis RL (2002) CAG/CTG repeat expansions at the HDL2 locus are a common cause of Huntington disease in black South Africans. Am J Hum Genet 71(4): 528-528.
17. Kremer B, Goldberg P, Andrew SE, et al. (1994) A Worldwide Study of the Huntington’s Disease Mutation: the sensitivity and specificity of measuring CAG repeats. N Engl J Med 330: 1401-1406.
18. Kumar N, Leonzino M, Hancock-Cerutti W, Horenkamp FA, LI P, et al. (2018) VPS13A and VPS13C are lipid transport proteins differentially localized at ER contact sites. J Cell Biol 217(10): 3625-3639.
19. Landoure G, Mochel F, Meilleur K, Ly M, Sangare M, et al. (2013) Novel mutation in the ATM gene in a Malian family with ataxia telangiectasia. J Neurol 260: 324-326.
20. Magazi DS, Krause A, Bonev V, Moagi M, Iqbal Z, et al. (2008) Huntington's disease: genetic heterogeneity in black African patients. S Afr Med J 98: 200-203.
21. Park JS, Thorsness MK, Policastro R, et al. (2016) Yeast Vps13 promotes mitochondrial function and is localized at membrane contact sites. Mol Biol Cell 27: 2435-2449.
22. Ross CA, Tabrizi SJ (2011) Huntington's disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 10: 83-98.
23. Stevanin G, Fujigasaki H, Lebre A-S, et al. (2003) Huntington’s disease-like phenotype due to trinucleotide repeat expansions in the TBP and JPH3 genes. Brain 126:1599-1603.
24. Triki C, Feki I, Meziou M, Turki H, Zahaf A, et al. (2000) Clinical, biological and genetic study of 24 patients with ataxia-telangiectasia from southern Tunisia. Rev Neurol 156: 634-637.
25. Velayos Baeza A, Dobson-Stone C, Rampoldi L, Bader B, Walker RH, et al. (2002) Chorea-Acanthocytosis. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, LJH B, Stephens K, Amemiya A, editors. Gene Reviews. Seattle: Seattle (WA): University of Washington: 1993-2019.
26. Wagstaff LA, Joffe R (1969) Ataxia-telangiectasia in a South African Bantu child. S Afr Med J 43: 662-664.